Literature DB >> 10230282

Nuclear medicine imaging in fever of unknown origin.

A M Peters1.   

Abstract

Patients presenting with undiagnosed fever generally fall into two broad groups: firstly, those with co-existing disease or recent surgery, and secondly those with pyrexia but who are otherwise more or less well. A pyogenic cause for fever is significantly more likely in the first group as compared with the second. Radionuclide agents which are currently freely available for investigating undiagnosed fever are labelled leukocytes, 67Ga, and radiolabelled human immunoglobulin (HIG). Labelled leukocytes are generally preferable in the group with co-existing disease (occult infection), whereas 67Ga should be used in the second group, which can appropriately be called fever of unknown origin (FUO). The lower specificity of 67G can be perceived as an advantage in this context in view of the wide range of pathologies capable of causing FUO. The role of HIG in undiagnosed fever is unsettled. In general, 67Ga is more helpful than labelled leukocytes when the cause of an FUO is intrathoracic, although the reverse is likely to be true for intra-abdominal causes, partly because of physiological excretion of 67Ga in the gut. Postoperative fever is an indication for a leukocyte scan. Patients with haematological malignancies occasionally present as an FUO, but patients with chronic renal disease should be approached as occult infection. Investigating children with undiagnosed fever is a particularly difficult problem. For the future, we need agents which are particularly effective for localising chronic inflammation and, of secondary importance, agents able to distinguish between infective and non-infective causes of inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230282

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN: 1125-0135


  8 in total

1.  67Ga scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

Review 2.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

3.  Fever of unknown origin: 98 cases from Saudi Arabia.

Authors:  Mahmoud A Moawad; Habib Bassil; Mona Elsherif; Abeer Ibrahim; Moustafa Elnaggar; Jameela Edathodu; Abdulaziz Alharthi; Muneerah Albugami; Ahmed Sabry; Mohammed Shoukri; Ibtisam Bakhsh; Ulrike Laudon
Journal:  Ann Saudi Med       Date:  2010 Jul-Aug       Impact factor: 1.526

4.  Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy.

Authors:  Andreas Kjaer; Anne-Mette Lebech; Annika Eigtved; Liselotte Højgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

5.  FDG-PET or PET/CT in Fever of Unknown Origin: The Diagnostic Role of Underlying Primary Disease.

Authors:  Nurhan Ergül; Tevfik Fikret Cermik
Journal:  Int J Mol Imaging       Date:  2011-03-03

6.  Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline.

Authors:  A Signore; F Jamar; O Israel; J Buscombe; J Martin-Comin; E Lazzeri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-31       Impact factor: 9.236

7.  The Diagnostic Role of FDG PET/CT in Patients with Fever of Unknown Origin.

Authors:  Nurhan Ergül; Metin Halac; Tevfik F Cermik; Resat Ozaras; Sait Sager; Cetin Onsel; Ilhami Uslu
Journal:  Mol Imaging Radionucl Ther       Date:  2011-04-01

8.  Ulcerative Colitis Activity Presenting as Fever of Unknown Origin, in a Patient with Longstanding Disease under Continuous Treatment with Mesalazine.

Authors:  Panagiota Voukelatou; Elissavet Sfendouraki; Theodoros Karianos; Sofia Saranti; Dimitrios Tsitsimelis; Ioannis Vrettos; Andreas Kalliakmanis
Journal:  Case Rep Med       Date:  2016-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.